Changing Diabetes??is Novo Nordisk’s response to the global diabetes challenge. Since the company was founded in Denmark more than 95 years ago, we have been changing diabetes. Our key contribution is to discover, develop and manufacture?better biological medicines and make them accessible to people with diabetes?throughout the world. However, it takes more than medicine to defeat diabetes.
By partnering with patients, policymakers, healthcare professionals and non-governmental organisations we are addressing diabetes risk factors in urban areas, ensuring that people with diabetes are diagnosed earlier and that they have access to adequate care to be able to live their lives with as few limitations as possible.
With two-thirds of all people with diabetes living in urban
areas1, cities are the frontline in the fight against
diabetes. Cities influence how people live, travel and
eat; factors which all have an impact on health. To understand the
root causes of type 2 diabetes and the social and cultural risk
factors, Novo Nordisk has initiated the Cities
Changing Diabetes programme in collaboration with a range of
Around 212 million people have undiagnosed type 2 diabetes
worldwide.1 Sadly, many already have complications by the
time they are diagnosed, including damage to their feet, eyes, kidneys
and heart.2 We are partnering with healthcare
professionals, patient organisations and policymakers to advocate for
the benefits of early diagnosis.?Each year on World Diabetes Day
hundreds of thousands of people are engaged in Novo Nordisk driven
awareness and screening activities.
Today, three in four people with diabetes live in low- and
middle-income countries1, where many lack access to
diabetes care either because it is not available or not affordable.
Novo Nordisk is working with partners to improve the availability,
accessibility, affordability and quality of healthcare.? Our largest
investment in improving access to care is through our funding of the
World Diabetes Foundation, but we also run
specific corporate access
to care programmes.
Many people with diabetes do not achieve desired health
outcomes3, which puts them at risk of developing
diabetes-related complications. While Novo Nordisk provides
a broad portfolio of treatment options and delivery devices, we know
that it takes more than medicine for people to live a full and healthy
life with diabetes. We address this by providing training of
healthcare providers, education of people with diabetes and engaging
in advocacy for patient-centred care.
1. International Diabetes Federation. IDF Diabetes Atlas. 8th
edn. Brussels, Belgium: International Diabetes Federation.
2.?WHO. Global report on diabetes. World Health Organization. 2016.
3.?Hart JT. Rule of Halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care. Br J Gen Pract. 1992;42(356):116-119. The ‘Rule of Halves’ is used to describe the global diabetes situation. Actual rates of diagnosis, treatment, targets and outcomes vary in different countries.